Your Research software will become a key element of Almac Clinical Technologies and will enhance the experience for participants, sites, and sponsors alike. A phased rollout is planned to start mid-2025, with broader expansion anticipated later in the year.
As the clinical research landscape becomes increasingly complex, the need for efficient, high-quality, and participant-focused tools is greater than ever. Your Research’s advanced solutions and expertise in participant-centric technology complement Almac’s current offerings, enabling Almac to provide industry leading clinical trial technology, expertise, and seamless service at every stage along the participant’s journey.
These new solutions will provide a seamless clinical trial experience making it easier for sites and participants to engage with the study, and sponsors to gather and analyse data in real-time. The acquisition reflects Almac Clinical Technologies’ proactive approach in anticipating and solving key challenges faced in the clinical trial process.
Valarie Higgins, President and Managing Director of Almac Clinical Technologies, said: “Almac’s acquisition of Your Research signifies a bold step towards innovation in clinical trials. By prioritising a service-driven approach, Almac is not just enhancing our software offerings; we are transforming the clinical trial experience for participants, sites, and sponsors.”
Kees Van Ooik, Co-Founder of Your Research, added: “Almac’s dedication to service excellence and innovation aligns perfectly with Your Research’s data and participant management system. Paired alongside Almac’s industry leading IXRS®3 IRT solution, we will provide trial stakeholders with an unprecedented level of insight and automation, further increasing data quality and adherence while making it easier to navigate complex clinical trial processes and the current multitude of systems.”
Cheryl Kole, Vice President, Solution Strategy and Commercialisation said: “This acquisition is an exciting advancement for Almac! It enables us to deliver a wider array of services, further reinforcing our commitment to delivering trusted solutions and support for clinical trials.”
